000130830 001__ 130830
000130830 005__ 20240228145554.0
000130830 0247_ $$2doi$$a10.2967/jnumed.116.189233
000130830 0247_ $$2pmid$$apmid:28473595
000130830 0247_ $$2ISSN$$a0022-3123
000130830 0247_ $$2ISSN$$a0097-9058
000130830 0247_ $$2ISSN$$a0161-5505
000130830 0247_ $$2ISSN$$a1535-5667
000130830 0247_ $$2ISSN$$a2159-662X
000130830 0247_ $$2altmetric$$aaltmetric:19941300
000130830 037__ $$aDKFZ-2017-05908
000130830 041__ $$aeng
000130830 082__ $$a610
000130830 1001_ $$aKesch, Claudia$$b0
000130830 245__ $$aIntraindividual Comparison of (18)F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study.
000130830 260__ $$aNew York, NY$$bSoc.$$c2017
000130830 3367_ $$2DRIVER$$aarticle
000130830 3367_ $$2DataCite$$aOutput Types/Journal article
000130830 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1533902674_22843
000130830 3367_ $$2BibTeX$$aARTICLE
000130830 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130830 3367_ $$00$$2EndNote$$aJournal Article
000130830 520__ $$a(68)Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT represents an advanced method for the staging of primary prostate cancer (PCa) and diagnosis of recurrent or metastatic PCa. However, because of the narrow availability of (68)Ga the development of alternative tracers is of high interest. The objective of this study was to examine the value of the new PET tracer (18)F-PSMA-1007 for the staging of local disease by comparing it with multiparametric MRI (mpMRI) and radical prostatectomy (RP) histopathology. Methods: In 2016, (18)F-PSMA-1007 PET/CT was performed in 10 men with biopsy-confirmed high-risk PCa. Nine patients underwent mpMRI in the process of primary diagnosis. Consecutively, RP was performed in all 10 men. Agreement analysis was performed retrospectively. PSMA staining was added for representative sections in RP specimen slices. Localization and agreement analysis of (18)F-PSMA-1007 PET/CT, mpMRI, and RP specimens was performed by dividing the prostate into 38 sections as described in the prostate imaging reporting and data system (PI-RADS) (version 2). Sensitivity, specificity, positive predictive values, negative predictive values (NPVs), and accuracy were calculated for total and near-total agreement. Results:(18)F-PSMA-1007 PET/CT had an NPV of 68% and an accuracy of 75%, and mpMRI had an NPV of 88% and an accuracy of 73% for total agreement. Near-total agreement analysis resulted in an NPV of 91% and an accuracy of 93% for (18)F-PSMA-1007 PET/CT and 91% and 87% for mpMRI, respectively. Retrospective combination of mpMRI and PET/CT had an accuracy of 81% for total and 93% for near-total agreement. Conclusion: Comparison with RP histopathology demonstrates that (18)F-PSMA-1007 PET/CT is promising for accurate local staging of PCa.
000130830 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000130830 588__ $$aDataset connected to CrossRef, PubMed,
000130830 7001_ $$aVinsensia, Maria$$b1
000130830 7001_ $$0P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aRadtke, Jan Philipp$$b2
000130830 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b3
000130830 7001_ $$aHeller, Martina$$b4
000130830 7001_ $$aEllert, Elena$$b5
000130830 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b6
000130830 7001_ $$aDuensing, Stefan$$b7
000130830 7001_ $$aGrabe, Nils$$b8
000130830 7001_ $$0P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aAfshar-Oromieh, Ali$$b9
000130830 7001_ $$aWieczorek, Kathrin$$b10
000130830 7001_ $$0P:(DE-He78)3373acf5d3b93adfd9ea973cf2d218aa$$aSchäfer, Martin$$b11
000130830 7001_ $$0P:(DE-He78)4f3bf0db0166b782272f523c85369931$$aNeels, Oliver$$b12
000130830 7001_ $$0P:(DE-He78)427023ff7e5f28a11e61fce0b4917b57$$aCardinale, Jens$$b13$$udkfz
000130830 7001_ $$aKratochwil, Clemens$$b14
000130830 7001_ $$aHohenfellner, Markus$$b15
000130830 7001_ $$0P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aKopka, Klaus$$b16
000130830 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b17
000130830 7001_ $$aHadaschik, Boris A$$b18
000130830 7001_ $$0P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aGiesel, Frederik$$b19$$eLast author
000130830 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.116.189233$$gVol. 58, no. 11, p. 1805 - 1810$$n11$$p1805 - 1810$$tJournal of nuclear medicine$$v58$$x2159-662X$$y2017
000130830 909CO $$ooai:inrepo02.dkfz.de:130830$$pVDB
000130830 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000130830 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000130830 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000130830 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000130830 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3373acf5d3b93adfd9ea973cf2d218aa$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000130830 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4f3bf0db0166b782272f523c85369931$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000130830 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)427023ff7e5f28a11e61fce0b4917b57$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000130830 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000130830 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000130830 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000130830 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000130830 9141_ $$y2017
000130830 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2015
000130830 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130830 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130830 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130830 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130830 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130830 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130830 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130830 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000130830 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000130830 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130830 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2015
000130830 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000130830 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x1
000130830 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x2
000130830 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x3
000130830 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x4
000130830 980__ $$ajournal
000130830 980__ $$aVDB
000130830 980__ $$aI:(DE-He78)C060-20160331
000130830 980__ $$aI:(DE-He78)E010-20160331
000130830 980__ $$aI:(DE-He78)E030-20160331
000130830 980__ $$aI:(DE-He78)E060-20160331
000130830 980__ $$aI:(DE-He78)L101-20160331
000130830 980__ $$aUNRESTRICTED